Investigating new engineering and modeling techniques for antibodies and biologics to improve efficiency, speed turnaround time, accelerate candidate screening and augment traditional experimental techniques.

Exploring the latest targets, technologies and formats enabling the next generation of oncology biotherapeutic drug development, including antibodies, cellular therapies and novel constructs.

Examining the next steps in broadening the application of the Multi-Attribute Method (MAM) and mass spectrometry-based tools in biopharmaceutical development.

Evaluating emerging and evolving recombinant protein expression and production tools at the convergence of biotechnology, genetic engineering, information technology, and bioprocessing.